Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(21)02718-5
PubMed Identifier: 34883053
Publication URI: http://europepmc.org/abstract/MED/34883053
Type: Journal Article/Review
Volume: 399
Parent Publication: Lancet (London, England)
Issue: 10319
ISSN: 0140-6736